# Substudy of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)

> **NCT02091882** · PHASE4 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 30 (actual)

## Conditions studied

- Device Latency

## Interventions

- **DRUG:** Placebo
- **COMBINATION_PRODUCT:** Combination product of Aripiprazole + IEM + Sensor + MIND1 Application

## Key facts

- **NCT ID:** NCT02091882
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-21
- **Primary completion:** 2014-04-18
- **Final completion:** 2014-04-18
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02091882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02091882, "Substudy of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02091882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*